Sun Pharma’s Promising Phase 3 Study on Tildrakizumab for Genital Psoriasis

Sun Pharmaceutical Industries Limited ((IN:SUNPHARMA)) announced an update on their ongoing clinical study.

Sun Pharmaceutical Industries Limited is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.’ The study aims to assess the effectiveness and safety of tildrakizumab, a drug designed to treat moderate to severe genital psoriasis, highlighting its potential significance in addressing this specific condition.

The intervention being tested is tildrakizumab, administered as a subcutaneous injection. The study compares the effects of tildrakizumab against a placebo to determine its efficacy in treating genital psoriasis.

This interventional study follows a randomized, parallel assignment model with double masking, meaning both participants and outcomes assessors are unaware of the treatment allocations. The primary purpose of the study is treatment-focused, aiming to evaluate the therapeutic benefits of tildrakizumab.

The study began on March 21, 2025, with an estimated completion date yet to be announced. The last update was submitted on July 1, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could influence market dynamics.

The ongoing study could significantly impact Sun Pharmaceutical’s stock performance, as positive results might boost investor confidence and market share in the dermatological treatment sector. Competitors in the psoriasis treatment market will be closely monitoring these developments.

The study is currently recruiting, with further details available on the ClinicalTrials portal.